Jun 10, 2025
ADCE-D01 is a first-in-class antibody-drug conjugate (ADC) targeting uPARAP, an endocytic receptor highly overexpressed in mesenchymal cancers including multiple soft tissue sarcoma subtypes The ADCElerate1 trial will enroll patients in the US and Europe Copenhagen,...
Apr 23, 2025
ADCE-T02 – a potential first and best-in-class topoisomerase-1 (Topo-1) inhibitor-based Antibody-Drug Conjugate (ADC) against Tissue Factor – demonstrates strong and broad preclinical efficacy and good tolerability ADCE-D01 – a first-in-class ADC...
Apr 1, 2025
Healthcare pioneer Laura Shawver, Ph.D. appointed Chair of the Board and industry veteran RoyBaynes M.D., Ph.D. appointed as independent, non-executive Director Fang Z. Ni, Pharm.D. named Chief Financial Officer Company expands global footprint by establishing U.S....
Feb 26, 2025
ADCE-T02 is a potential first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate (ADC) targeting tissue factor, a validated ADC target overexpressed in multiple solid tumors Phase I Tiffany-01 trial is designed to evaluate the safety, pharmacokinetics,...
Nov 25, 2024
Financing led by TCGX, including new investment from TPG, Orbimed Advisors, Venrock Healthcare Capital Partners, Surveyor Capital (a Citadel company), and Logos Capital, with participation from all existing investors Proceeds will be used to support the advancement of...
Oct 29, 2024
Copenhagen, Denmark, October 29th, 2024 – Adcendo ApS (“Adcendo”), a biotech company focused on the development of first-in-class ADCs for the treatment of cancers with a high unmet medical need, today announces that its CEO, Michael Pehl will join fellow...
